Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone


No votes yet
 
Related
ROVI holds its 2020 General Shareholders' Meeting
Today, Laboratorios Farmacéuticos Rovi, S.A. held its General Shareholders’ Meeting, where the year 2019, marked by significant growth, was...
5 min
20/10/2020
0 min
25/09/2020